Effect of Hypertonic Saline on Lung Function as Add-on Treatment in People With Cystic Fibrosis Receiving Dornase Alfa
Abstract
No abstract availableKeywords
Funding Information
- Cystic Fibrosis Foundation
This publication has 22 references indexed in Scilit:
- Investigating the effects of long-term dornase alfa use on lung function using registry dataJournal of Cystic Fibrosis, 2019
- The Cystic Fibrosis Foundation Patient Registry. Design and Methods of a National Observational Disease RegistryAnnals of the American Thoracic Society, 2016
- Factors associated with FEV1decline in cystic fibrosis: analysis of the ECFS Patient RegistryEuropean Respiratory Journal, 2013
- Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equationsEuropean Respiratory Journal, 2012
- Inhaled Hypertonic Saline in Infants and Children Younger Than 6 Years With Cystic FibrosisJAMA, 2012
- Understanding the natural progression in %FEV1decline in patients with cystic fibrosis: a longitudinal studyThorax, 2012
- Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTRMutationNew England Journal of Medicine, 2010
- Risk Factors For Rate of Decline in Forced Expiratory Volume in One Second in Children and Adolescents with Cystic FibrosisThe Journal of Pediatrics, 2007
- A Controlled Trial of Long-Term Inhaled Hypertonic Saline in Patients with Cystic FibrosisNew England Journal of Medicine, 2006
- Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trialThe Lancet, 2001